Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05519085




Registration number
NCT05519085
Ethics application status
Date submitted
25/08/2022
Date registered
29/08/2022
Date last updated
7/06/2024

Titles & IDs
Public title
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Scientific title
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Secondary ID [1] 0 0
2021-001957-30
Secondary ID [2] 0 0
CA057-001
Universal Trial Number (UTN)
Trial acronym
SUCCESSOR-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsed or Refractory Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - mezigdomide
Treatment: Drugs - Pomalidomide
Treatment: Drugs - Bortezomib
Treatment: Drugs - Dexamethasone

Experimental: MeziVd (mezigdomide, bortezomib and dexamethasone) -

Experimental: PVd (pomalidomide, bortezomib and dexamethasone) -


Treatment: Drugs: mezigdomide
Specified dose on specified days

Treatment: Drugs: Pomalidomide
Specified dose on specified days

Treatment: Drugs: Bortezomib
Specified dose on specified days

Treatment: Drugs: Dexamethasone
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS)
Timepoint [1] 0 0
From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years)
Secondary outcome [1] 0 0
Recommended mezigdomide dose
Timepoint [1] 0 0
Up to 12 Months
Secondary outcome [2] 0 0
Plasma concentrations of mezigdomide
Timepoint [2] 0 0
Up to 134 Days
Secondary outcome [3] 0 0
Overall Survival (OS)
Timepoint [3] 0 0
From date of randomization to date of death due to any cause (Up to approximately 5 years)
Secondary outcome [4] 0 0
Overall Response (OR)
Timepoint [4] 0 0
Up to approximately 5 years
Secondary outcome [5] 0 0
Complete Response (CR) or better
Timepoint [5] 0 0
Up to approximately 5 Years
Secondary outcome [6] 0 0
Very Good Partial Response (VGPR) or better
Timepoint [6] 0 0
Up to approximately 5 years
Secondary outcome [7] 0 0
Time to Response (TTR)
Timepoint [7] 0 0
Up to approximately 5 years
Secondary outcome [8] 0 0
Duration of Response (DOR)
Timepoint [8] 0 0
Up to approximately 5 years
Secondary outcome [9] 0 0
Time to Progression (TTP)
Timepoint [9] 0 0
Up to approximately 5 years
Secondary outcome [10] 0 0
Time to Next Treatment (TTNT)
Timepoint [10] 0 0
Up to approximately 5 years
Secondary outcome [11] 0 0
Progression-free Survival 2 (PFS-2)
Timepoint [11] 0 0
Up to approximately 5 years
Secondary outcome [12] 0 0
Minimal Residual Disease (MRD) negativity
Timepoint [12] 0 0
Up to approximately 5 years
Secondary outcome [13] 0 0
Number of participants with Adverse Events (AEs)
Timepoint [13] 0 0
Up to approximately 5 years
Secondary outcome [14] 0 0
Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) scores
Timepoint [14] 0 0
Up to approximately 5 years
Secondary outcome [15] 0 0
Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) score
Timepoint [15] 0 0
Up to approximately 5 years

Eligibility
Key inclusion criteria
Inclusion Criteria

- Participant has documented diagnosis of MM and measurable disease, defined as any of the
following:.

i) M-protein = 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or.

ii) M-protein = 200 milligrams (mg) per 24-hour urine collection by urine protein
electrophoresis (uPEP).

iii) For participants without measurable disease in sPEP or uPEP: serum free light chain
(sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC
ratio.

- Participants received 1 to 3 prior lines of antimyeloma therapy.

- Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma
therapy.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

- Participant has had progression during treatment or within 60 days of the last dose of
a proteasome inhibitor, except as noted below:.

i) Subjects who progressed while being treated with, or within 60 days of last dose of
bortezomib maintenance given once every 2 weeks or less are not excluded.

- For participants with prior treatment of a bortezomib containing regimen, the best
response achieved was not a minimal response (MR) or better, or participant
discontinued bortezomib due to toxicity.

- Participant has had prior treatment with mezigdomide or pomalidomide.

- Other protocol-defined Inclusion/Exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/09/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/11/2033
Actual
Sample size
Target
810
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [2] 0 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [3] 0 0
Wollongong Hospital-Illawarra Cancer Care Centre - Wollongong
Recruitment hospital [4] 0 0
Sunshine Coast University Hospital - Birtinya
Recruitment hospital [5] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [6] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [7] 0 0
St Vincent's Hospital - Melbourne
Recruitment hospital [8] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
2298 - Waratah
Recruitment postcode(s) [3] 0 0
2500 - Wollongong
Recruitment postcode(s) [4] 0 0
4575 - Birtinya
Recruitment postcode(s) [5] 0 0
3128 - Box Hill
Recruitment postcode(s) [6] 0 0
3004 - Melbourne
Recruitment postcode(s) [7] 0 0
3065 - Melbourne
Recruitment postcode(s) [8] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Kansas
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Mississippi
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New Mexico
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Utah
Country [19] 0 0
United States of America
State/province [19] 0 0
Virginia
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
United States of America
State/province [21] 0 0
Wisconsin
Country [22] 0 0
Argentina
State/province [22] 0 0
Buenos Aires
Country [23] 0 0
Argentina
State/province [23] 0 0
Córdoba
Country [24] 0 0
Argentina
State/province [24] 0 0
Río Negro
Country [25] 0 0
Argentina
State/province [25] 0 0
Santa Fe
Country [26] 0 0
Austria
State/province [26] 0 0
Wien
Country [27] 0 0
Austria
State/province [27] 0 0
Krems an der Donau
Country [28] 0 0
Austria
State/province [28] 0 0
Leoben
Country [29] 0 0
Austria
State/province [29] 0 0
St. Pölten
Country [30] 0 0
Belgium
State/province [30] 0 0
Limburg
Country [31] 0 0
Belgium
State/province [31] 0 0
Oost-Vlaanderen
Country [32] 0 0
Belgium
State/province [32] 0 0
Antwerpen
Country [33] 0 0
Brazil
State/province [33] 0 0
Bahia
Country [34] 0 0
Brazil
State/province [34] 0 0
Rio Grande Do Sul
Country [35] 0 0
Brazil
State/province [35] 0 0
Santa Catarina
Country [36] 0 0
Brazil
State/province [36] 0 0
São Paulo
Country [37] 0 0
Brazil
State/province [37] 0 0
Rio de Janeiro
Country [38] 0 0
Brazil
State/province [38] 0 0
Sao Paulo
Country [39] 0 0
Canada
State/province [39] 0 0
Quebec
Country [40] 0 0
Chile
State/province [40] 0 0
Región Metropolitana De Santiago
Country [41] 0 0
Chile
State/province [41] 0 0
Valparaíso
Country [42] 0 0
China
State/province [42] 0 0
Beijing
Country [43] 0 0
China
State/province [43] 0 0
Chongqing
Country [44] 0 0
China
State/province [44] 0 0
Fujian
Country [45] 0 0
China
State/province [45] 0 0
Guangdong
Country [46] 0 0
China
State/province [46] 0 0
Guangxi
Country [47] 0 0
China
State/province [47] 0 0
Hebei
Country [48] 0 0
China
State/province [48] 0 0
Henan
Country [49] 0 0
China
State/province [49] 0 0
Hubei
Country [50] 0 0
China
State/province [50] 0 0
Hunan
Country [51] 0 0
China
State/province [51] 0 0
Jiangsu
Country [52] 0 0
China
State/province [52] 0 0
Liaoning
Country [53] 0 0
China
State/province [53] 0 0
Shaanxi
Country [54] 0 0
China
State/province [54] 0 0
Shandong
Country [55] 0 0
China
State/province [55] 0 0
Shanghai
Country [56] 0 0
China
State/province [56] 0 0
Shanxi
Country [57] 0 0
China
State/province [57] 0 0
Sichuan
Country [58] 0 0
China
State/province [58] 0 0
Tianjin
Country [59] 0 0
China
State/province [59] 0 0
Xinjiang
Country [60] 0 0
China
State/province [60] 0 0
Yunnan
Country [61] 0 0
China
State/province [61] 0 0
Zhejiang
Country [62] 0 0
China
State/province [62] 0 0
Taiyuan
Country [63] 0 0
Czechia
State/province [63] 0 0
Brno-mesto
Country [64] 0 0
Czechia
State/province [64] 0 0
Praha
Country [65] 0 0
Finland
State/province [65] 0 0
Pohjois-Savo
Country [66] 0 0
Finland
State/province [66] 0 0
Helsinki
Country [67] 0 0
France
State/province [67] 0 0
Alsace
Country [68] 0 0
France
State/province [68] 0 0
Aquitaine
Country [69] 0 0
France
State/province [69] 0 0
Gard
Country [70] 0 0
France
State/province [70] 0 0
Nord
Country [71] 0 0
France
State/province [71] 0 0
Rhône-Alpes
Country [72] 0 0
France
State/province [72] 0 0
Clermont-Ferrand
Country [73] 0 0
France
State/province [73] 0 0
Limoges
Country [74] 0 0
France
State/province [74] 0 0
Nantes
Country [75] 0 0
France
State/province [75] 0 0
Tours
Country [76] 0 0
France
State/province [76] 0 0
Île-de-France
Country [77] 0 0
Germany
State/province [77] 0 0
Hessen
Country [78] 0 0
Germany
State/province [78] 0 0
Nordrhein-Westfalen
Country [79] 0 0
Germany
State/province [79] 0 0
Schleswig-Holstein
Country [80] 0 0
Germany
State/province [80] 0 0
Hamburg
Country [81] 0 0
Germany
State/province [81] 0 0
Tuebingen
Country [82] 0 0
Greece
State/province [82] 0 0
Attikí
Country [83] 0 0
Greece
State/province [83] 0 0
Thessaloníki
Country [84] 0 0
India
State/province [84] 0 0
Gujarat
Country [85] 0 0
India
State/province [85] 0 0
Haryana
Country [86] 0 0
India
State/province [86] 0 0
Karnataka
Country [87] 0 0
India
State/province [87] 0 0
Tamil Nadu
Country [88] 0 0
India
State/province [88] 0 0
Uttar Pradesh
Country [89] 0 0
India
State/province [89] 0 0
Ludhiana
Country [90] 0 0
India
State/province [90] 0 0
Puducherry
Country [91] 0 0
Ireland
State/province [91] 0 0
Connaught
Country [92] 0 0
Ireland
State/province [92] 0 0
Cork
Country [93] 0 0
Ireland
State/province [93] 0 0
Dublin
Country [94] 0 0
Israel
State/province [94] 0 0
HaMerkaz
Country [95] 0 0
Israel
State/province [95] 0 0
HaTsafon
Country [96] 0 0
Israel
State/province [96] 0 0
Tall Abib
Country [97] 0 0
Israel
State/province [97] 0 0
Yerushalayim
Country [98] 0 0
Israel
State/province [98] 0 0
Peatch Tikva
Country [99] 0 0
Italy
State/province [99] 0 0
Sicilia
Country [100] 0 0
Italy
State/province [100] 0 0
Bologna
Country [101] 0 0
Italy
State/province [101] 0 0
Pavia
Country [102] 0 0
Italy
State/province [102] 0 0
Roma
Country [103] 0 0
Japan
State/province [103] 0 0
Chiba
Country [104] 0 0
Japan
State/province [104] 0 0
Fukuoka
Country [105] 0 0
Japan
State/province [105] 0 0
Hokkaido
Country [106] 0 0
Japan
State/province [106] 0 0
Iwate
Country [107] 0 0
Japan
State/province [107] 0 0
Kanagawa
Country [108] 0 0
Japan
State/province [108] 0 0
Saitama
Country [109] 0 0
Japan
State/province [109] 0 0
Shizuoka
Country [110] 0 0
Japan
State/province [110] 0 0
Tokyo
Country [111] 0 0
Japan
State/province [111] 0 0
Hiroshima
Country [112] 0 0
Japan
State/province [112] 0 0
Kumamoto
Country [113] 0 0
Japan
State/province [113] 0 0
Nagasaki
Country [114] 0 0
Korea, Republic of
State/province [114] 0 0
Busan-gwangyeoksi
Country [115] 0 0
Korea, Republic of
State/province [115] 0 0
Gyeonggido
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Jeonranamdo
Country [117] 0 0
Korea, Republic of
State/province [117] 0 0
Seoul Teugbyeolsi
Country [118] 0 0
Korea, Republic of
State/province [118] 0 0
Seoul-teukbyeolsi [Seoul]
Country [119] 0 0
Korea, Republic of
State/province [119] 0 0
Seoul-teukbyeolsi
Country [120] 0 0
Korea, Republic of
State/province [120] 0 0
Seoul
Country [121] 0 0
New Zealand
State/province [121] 0 0
Bay Of Plenty
Country [122] 0 0
New Zealand
State/province [122] 0 0
Otago
Country [123] 0 0
New Zealand
State/province [123] 0 0
Auckland
Country [124] 0 0
Poland
State/province [124] 0 0
Kujawsko-pomorskie
Country [125] 0 0
Poland
State/province [125] 0 0
Mazowieckie
Country [126] 0 0
Poland
State/province [126] 0 0
Malopolskie
Country [127] 0 0
Poland
State/province [127] 0 0
Pomorskie
Country [128] 0 0
Poland
State/province [128] 0 0
Wielkopolskie
Country [129] 0 0
Portugal
State/province [129] 0 0
Braga
Country [130] 0 0
Portugal
State/province [130] 0 0
Lisbon
Country [131] 0 0
Portugal
State/province [131] 0 0
Porto
Country [132] 0 0
Puerto Rico
State/province [132] 0 0
San Juan
Country [133] 0 0
Romania
State/province [133] 0 0
Bucharest
Country [134] 0 0
Romania
State/province [134] 0 0
Cluj Napoca
Country [135] 0 0
Romania
State/province [135] 0 0
Iasi
Country [136] 0 0
Spain
State/province [136] 0 0
Balears [Baleares]
Country [137] 0 0
Spain
State/province [137] 0 0
Catalunya [Cataluña]
Country [138] 0 0
Spain
State/province [138] 0 0
Illes Balears
Country [139] 0 0
Spain
State/province [139] 0 0
Murcia, Región De
Country [140] 0 0
Spain
State/province [140] 0 0
Málaga
Country [141] 0 0
Spain
State/province [141] 0 0
Cáceres
Country [142] 0 0
Spain
State/province [142] 0 0
León
Country [143] 0 0
Spain
State/province [143] 0 0
Madrid
Country [144] 0 0
Turkey
State/province [144] 0 0
Ankara
Country [145] 0 0
Turkey
State/province [145] 0 0
Istanbul
Country [146] 0 0
Turkey
State/province [146] 0 0
Izmir
Country [147] 0 0
Turkey
State/province [147] 0 0
Kayseri
Country [148] 0 0
Turkey
State/province [148] 0 0
Samsun
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Cambridgeshire
Country [150] 0 0
United Kingdom
State/province [150] 0 0
England
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Great Britain
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Greater London
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Leicestershire
Country [154] 0 0
United Kingdom
State/province [154] 0 0
London, City Of
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Barnet
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Newcastle upon Tyne
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Stoke-on-Trent

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Celgene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480),
bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd)
in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to
3 prior lines of therapy and who have had prior lenalidomide exposure.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05519085
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Address 0 0
Country 0 0
Phone 0 0
855-907-3286
Fax 0 0
Email 0 0
Clinical.Trials@bms.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05519085